Taking into account higher risk of severe coronavirus disease 2019 or death among patients
with cancer, as well as impaired immunogenicity after anti-SARS-CoV-2 vaccines, in …

Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been
shown to impose a higher burden on cancer patients than on the general population …

Background COVID-19 messenger RNA (mRNA) vaccines have demonstrated efficacy and
effectiveness in preventing symptomatic COVID-19, while being relatively safe in trial …

Background Cancer patients particularly those with hematological malignancies are at
higher risk of affecting by severe coronavirus disease 2019 (COVID-19). Due to the …

Since its emergence, coronavirus disease 2019 (COVID-19) has affected the entire world
and all commerce and industries, including healthcare systems. COVID-19 adversely affects …

We have vaccinated 392 patients with two doses of mRNA COMIRNATY vaccine with an
overall antibody response of 70%(best in cMPN, worst in CLL). We have then vaccinated 80 …

To reveal waning humoral immunity after second dose BNT162b2 vaccinations in a rural
Japanese community and determine factors affecting antibody titers. We aimed to report …

Vaccines are the most effective means to prevent the potentially deadly effects of SARS-CoV-
2 infection, but not all vaccinated individuals gain the same degree of protection. Patients …

Background Patients with cancer are at high risk of severe or lethal COVID-19. The impact of
SARS-COV-2 vaccination on the risk of developing COVID-19 was investigated in an …

Simple Summary Coronavirus disease 2019 (COVID-19) is the greatest present-day public
and global health challenge, and patients with cancer are especially vulnerable …